Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- May 24, 2016
Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its...
- May 5, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results and provides an update on the progress of its drug development pipeline. "During the first quarter, we continued to...
- Apr 19, 2016Writing in ONdrugDelivery Magazine, CSO David L. Hava describes how innovative new strategies for delivering inhaled drugs to the lungs can fight serious bacterial and fungal infections.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to...
- Mar 10, 20162015 was a transformational year - lead assets for COPD and cystic fibrosis continue to progress in clinical development.
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Company's recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline. "2015...
-
Mar 10, 2016
Dear Fellow Shareholders, Continuing our Momentum As Pulmatrix moves into 2016, we wanted to describe to our shareholders the significant progress the Company is making—and how...
